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In the first issue of this new journal Denvir and colleagues
[1] touch on a subject which is probably the single most
important threat to cardiac surgery- the increasing ten-
dency of some cardiologists to treat patients with severe
coronary artery disease without a surgical opinion.
Increasingly, the best interests of patients are no longer at
the heart of the matter.
Throughout the developed world cardiac surgery faces
increasing challenges from percutaneous intervention,
currently with revascularisation, but potentially soon for
valve replacement as well. The spectacular growth of PCI
in the UK over the last five years is typical for many devel-
oped countries [2]. Since 1998 in the UK the ratio of
PCI:CABG has increased from 1:1 to almost 3:1. This
change in practice is likely to continue or even accelerate
as the recent European Society of Cardiology [3] and the
American Heart Association [4] guidelines recommend
that PCI can be considered as the initial treatment strategy
for most patients with multi-vessel disease. Furthermore
these guidelines along with those of the British Cardiac
Society [2], written almost exclusively by cardiologists (75
cardiologists and two surgeons), do not even recommend
a surgical opinion, effectively dismissing the more effec-
tive option of CABG. In effect these guidelines promote
abandonment of the multidisciplinary approach to multi-
vessel ischaemic heart disease.
Most worrying, however, is that the European and Ameri-
can guidelines simply fly in the face of all the available
evidence. The guidelines are based on a fundamentally
flawed misunderstanding and/or misinterpretation of 15
randomised trials of PCI (five of which used stents) versus
CABG. These trials reported that while CABG reduced the
need for further intervention almost fourfold in patients
with 'multi-vessel' disease there was no difference in sur-
vival between PCI and CABG. Yet this is simply not true
for most patients with real multivessel ischaemic heart
disease. The apparent similarity in survival was 'manufac-
tured' by only including low risk patients in the trials. All
the trial patients had normal ventricular function and
around 70% had single or double vessel disease, a popu-
lation in whom it had already been established that there
was little prognostic benefit from surgery [5]. Around
95% of all the screened patients were excluded from these
trials and in particular those who are known to benefit
from surgery i.e. those with left main disease, severe and/
or complex triple vessel disease, occluded vessels and with
impaired ventricular function.
Accordingly, I previously wrote in the British medical
Journal that these trials were in effect inherently biased
against the prognostic benefits of surgery [6]. I also
pointed out that the trials were subsequently presented in
the medical and lay press in a disingenuous fashion. They
were styled and titled as trials of patients with multi-vessel
disease to imply that the trial patients had the typical pat-
tern of triple vessel disease which is present in over 90%
of CABG patients in the real world. Reporting of the trials
and accompanying supportive editorials, almost exclu-
sively written by cardiologists, disingenuously ignored or
fleetingly mentioned their fundamental limitations.
Yet these trials have now been used to establish PCI as the
default treatment for patients undergoing coronary revas-
cularisation. They ignore the overwhelmingly strong evi-
dence in favour of CABG in real clinical practice. In the
New York registry of almost 60,000 risk matched patients
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in the "real world", those patients who received CABG
rather than PCI had a highly significant absolute reduc-
tion in mortality of around 35% at three years and a seven
fold reduction in the need for further intervention (5% vs
35%) [7]. Similar evidence in favour of CABG has also
been reported from the Cleveland Clinic [8] and the
effects are further magnified in diabetic patients [9]. An
accompanying editorial to the New York Registry pointed
out that the survival benefit of CABG is because as the
bypass graft is placed to the mid coronary vessel, surgery
deals not only with the culprit lesion, which can be of any
complexity, but also has a protective effect against future
culprit lesions.
As evidenced and inappropriately supported by the cur-
rent ESC and AHA guidelines, an increasing proportion of
current interventional cardiology practice appears to be
driven by those either ignorant of or unwilling to
acknowledge real facts. And evidence based medicine
appears ineffectual against misleading trials and data
backed and promoted by a multi-billion dollar industry.
So what is the best way to ensure that the patient at least
has access to balanced advice regarding most effective
treatment? I believe that this can only be achieved by the
patient being advised by a multidisciplinary team, includ-
ing a surgeon, who practice evidence based medicine [5].
The major European, Asian and American colleges of Car-
diothoracic surgery should, individually and collectively,
issue consensus guidelines to this effect. Ensuring that
patients are appropriately and adequately informed
ensures that they can make a rational decision about their
treatment and sits well with medical and governmental
recommendations to that effect. It might also provide
some sense of check and balance to those cardiologists
who, to the detriment of the patients, currently boast that
they "do not refer patients for coronary artery bypass graft-
ing".
References
1. Denvir MA, Pell JP, Lee AJ, Rysdale J, Prescott RJ, Eteiba H, Walker A,
Mankad P, Starkey IR: Variations in clinical decision-making
between cardiologists and cardiac surgeon: a case for man-
agement by multidisciplinary teams?  Journal of Cardiothoracic
Surgery 2006, 1:2.
2. Dawkins KD, Gershlick T, de Belder M, et al.: Joint Working Group
on Percutaneous Coronary Intervention of the British Car-
diovascular Intervention Society and the British Cardiac
Society. Percutaneous coronary intervention: recommenda-
tions for good practice and training.  Heart 2005:1-27.
3. Silber S, Albertsson P, Aviles FF, et al.: Task Force for Percutane-
ous Coronary Interventions of the European Society of Car-
diology. Guidelines for percutaneous coronary
interventions. The Task Force for Percutaneous Coronary
Interventions of the European Society of Cardiology.  Eur
Heart J 2005, 26:804-47.
4. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al.: American College
of Cardiology/American Heart Association Task Force on
Practice Guidelines; American College of Cardiology/Amer-
ican Heart Association/Society for Cardiovascular Angiogra-
phy and Interventions Writting Committee to Update the
2001 Guidelines for Percutaneous Coronary Intervention.
Circulation 2006, 113:156-75.
5. Yusuf S, Zucker D, Peduzzi P, et al.: Effect of coronary artery
bypass graft surgery on survival: overview of 10-year results
from randomised trials by the Coronary Artery Bypass Graft
Surgery Trialists Collaboration.  Lancet 1994, 344:563-70.
6. Taggart DP: Surgery is the best intervention for severe coro-
nary artery disease.  BMJ 2005, 330:785-6.
7. Hannan EL, Racz MJ, Walford G, et al.: Long-term outcomes of
coronary-artery bypass grafting versus stent implantation.  N
Engl J Med 2005, 352:2174-83.
8. Brener SJ, Lytle BW, Casserly IP, et al.: Propensity analysis of long-
term survival after surgical or percutaneous revasculariza-
tion in patients with multivessel coronary artery disease and
high-risk features.  Circulation 2004, 109:2290-5.
9. Niles NW, McGrath PD, Malenka D, Northern New England Cardio-
vascular Disease Study Group, et al.: Survival of patients with dia-
betes and multivessel coronary artery disease after surgical
or percutaneous coronary revascularization: results of a
large regional prospective study. Northern New England
Cardiovascular Disease Study Group.  J Am Coll Cardiol 2001,
37:1008-15.